Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06262464
Other study ID # 17.361/ 07.12.2023
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 9, 2024
Est. completion date April 1, 2024

Study information

Verified date March 2024
Source Babes-Bolyai University
Contact Roxana Cardo?, PhD
Phone 0040751477323
Email roxanaoltean@psychology.ro
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this randomised clinical trial is to test the efficacy of a prevention program for adult who are at risk of developing OCD, thus constituting a form of tertiary prevention.


Description:

After being informed about the study and giving written informed consent, all eligible participants will be randomised into the experimental group or the control group (TAU). Participants will be blind to the group allocation. The experimental group will undergo a two weeks OCD prevention program, consisting of three group sessions per week. The control group will not receive any intervention. Researchers will compare the experimental group to the control group to test wether the prevention programme is efficient in reducing OCD symptomatology.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date April 1, 2024
Est. primary completion date March 29, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - age over 18 Exclusion Criteria: - clinically diagnosed OCD - current psychiatric/psychotherapeutic treatment - personality disorder diagnosis - suicidal ideation

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Prevention
A cognitive-behavioural prevention programme.

Locations

Country Name City State
Romania Babes-Bolyai University, Faculty of Psychology and Educational Sciences, Department of Clinical Psychology and Psychotherapy Cluj-Napoca

Sponsors (2)

Lead Sponsor Collaborator
Babes-Bolyai University Romanian National Authority for Scientific Research

Country where clinical trial is conducted

Romania, 

Outcome

Type Measure Description Time frame Safety issue
Other Change from baseline in life quality on the WHOQOL-BREF after the intervention The WHOQOL-BREF is a validated self-report instrument assessing life quality in adults.
Change = end of intervention score - baseline score
Baseline and Week 2
Other Change from baseline in irrationality on the ATQ after the intervention The ABS-AV is a validated self-report instrument assessing irrationality in adults. Possible scores range from 24 to 120 Change = end of intervention score - baseline score Baseline and Week 2
Other Change from baseline in global health on the GHQ-12 after the intervention The GHQ-12 is a validated self-report instrument assessing global health in adults.
Possible scores range from 0 to 36. Change = end of intervention score - baseline score
Baseline and Week 2
Primary Change from baseline in OCD symptoms on the OCI-R after the intervention The OCI-R is a validated self-report instrument assessing OCD symptoms. Possible scores range from 0 to 72. Change = end of intervention score - baseline score Baseline and Week 2
Primary Change from baseline in depressive symptoms on the PHQ-9 after the intervention The PHQ-9 is a validated self-report instrument assessing depressive symptoms. Possible scores range from 0 to 27.
Change = end of intervention score - baseline score
Baseline and Week 2
Primary Change from baseline in anxiety symptoms on the GAD-7 after the intervention The GAD-7 is a validated self-report instrument assessing anxiety symptoms. Possible scores range from 0 to 21.
Change = end of intervention score - baseline score
Baseline and Week 2
Secondary Change from baseline in experiential avoidance on the EAQ after the intervention The EAQ is a validated self-report instrument assessing experiential avoidance. Possible scores range from 15 to 90.
Change = end of intervention score - baseline score
Baseline and Week 2
Secondary Change from baseline in cognitive distortions on the OBQ-44 after the intervention The OBQ-44 is a validated self-report instrument assessing cognitive distortions in OCD. Possible scores range from 7 to 308.
Change = end of intervention score - baseline score
Baseline and Week 2
Secondary Change from baseline in uncertainty intolerance on the IUS after the intervention The IUS is a validated self-report instrument assessing intolerance of uncertainty. Possible scores range from 27 to 135.
Change = end of intervention score - baseline score
Baseline and Week 2
Secondary Change from baseline in resilience on the RSA after the intervention The RSA is a validated self-report instrument assessing resilience in adults. Possible scores range from 43 to 215.
Change = end of intervention score - baseline score
Baseline and Week 2
See also
  Status Clinical Trial Phase
Recruiting NCT04934007 - Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder N/A
Recruiting NCT04071990 - Family Involvement in CBGT of OCD: a Randomized Controlled Trial N/A
Completed NCT02541968 - Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Recruiting NCT05391503 - Light Therapy for Obsessive-compulsive Disorder (OCD) N/A
Recruiting NCT04539951 - Pragmatic Trial of Obsessive-compulsive Disorder Phase 2
Completed NCT03416504 - Methods for Managing Intrusive Thoughts N/A
Not yet recruiting NCT06029738 - Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD N/A
Recruiting NCT02844049 - European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS N/A
Terminated NCT02909660 - What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder N/A
Completed NCT02911324 - Cannabinoid Medication for Adults With OCD Phase 1/Phase 2
Terminated NCT02234011 - A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder Phase 2
Completed NCT02217995 - Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients N/A
Withdrawn NCT01953042 - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders N/A
Completed NCT02655926 - Deep Brain Stimulation for Severe Obsessive Compulsive Disorder N/A
Terminated NCT00758966 - Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder Phase 2
Completed NCT00742664 - Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project Phase 1/Phase 2
Completed NCT04919785 - Deep Brain Stimulation in Severe Obsessive-compulsive Disorder N/A
Completed NCT00523718 - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Phase 2
Completed NCT00074815 - Treatment of Obsessive Compulsive Disorder in Children Phase 3